Showing 3003 results
-
Press release /Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion¹˒²MRI…
-
Clinical Trials /
-
Press release /Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone1 Benefit increased over time in invasive disease-free survival and across key secondary endpoints1-3 Patients off…
-
Clinical Trials /
-
Press release /Cosentyx® (secukinumab) becomes first and only IL-17A inhibitor approved in Europe for adults with PMR,1 a common inflammatory rheumatic disease with limited advanced treatment options2-6Approval…
-
Story /Novartis has earned a spot among the world’s top performers, ranking #19 in TIME and Statista’s World’s Best Companies 2026 – a significant rise from #114 last year. The recognition reflects progress across three critical areas: business performance, workplace experience, and sustainability.